Related Experiment Video
Updated: Mar 10, 2026
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
Practical Considerations in Managing Relapsed Multiple Myeloma
Amit Agarwal1, Eric Chow2, Manisha Bhutani2
1Division of Hematology-Oncology, University of Arizona Cancer Center, Tucson, AZ.
Abstract:
Considerable advances have been made in the treatment of relapsed and relapsed/refractory multiple myeloma, with numerous novel agents and combination strategies receiving regulatory approval worldwide during the past several years. An increasing body of phase III data has clearly demonstrated increased overall response rates, improved depths of response, and more durable responses when a third novel agent is incorporated into lenalidomide-dexamethasone and bortezomib-dexamethasone platforms, in most cases with acceptable toxicity. The carfilzomib-dexamethasone doublet has also demonstrated promising activity. With this rapid progress has come many new questions. We review the data supporting the use of these novel treatment paradigms for relapsed/refractory multiple myeloma, discuss the place of autologous and allogeneic hematopoietic stem cell transplantation in this rapidly evolving treatment space, and propose strategies to best use these regimens, considering the disease, host, and previous treatment factors.
Insights
Novel agents and combinations improve outcomes for relapsed/refractory multiple myeloma. This review discusses new treatment paradigms, stem cell transplantation, and personalized strategies for managing this complex blood cancer.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Multiple myeloma treatment has advanced significantly with new drug approvals.
- Phase III data support incorporating a third novel agent into existing platforms.
Purpose of the Study:
- To review novel treatment paradigms for relapsed/refractory multiple myeloma.
- To discuss the role of stem cell transplantation in current treatment strategies.
- To propose personalized treatment approaches based on disease and patient factors.
Main Methods:
- Review of phase III clinical trial data.
- Analysis of regulatory approvals for novel agents.
- Discussion of autologous and allogeneic stem cell transplantation outcomes.
Main Results:
- Combination therapies demonstrate improved response rates and durability.
- Novel agents show promising activity in relapsed/refractory multiple myeloma.
- Toxicity profiles are generally acceptable with novel combinations.
Conclusions:
- Novel agents and combinations represent a significant advance in multiple myeloma therapy.
- Stem cell transplantation remains a key consideration in treatment sequencing.
- Personalized strategies are essential for optimizing outcomes in relapsed/refractory disease.
More Related Videos
09:41An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
10:04Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
Published on: May 1, 2015
Related Concept Videos
01:22Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
01:29Therapeutic Drug Monitoring: Affecting Factors
01:22Myocarditis IV: Nursing Management
01:16Kidney Transplant III: Nursing Management
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:56Treatment Resistant Cancers